Collaborations & Alliances

ProBioGen Achieves Merus Milestone

Phase I trial will leverage GlymaxX cancer cell-killing enhancement antibody technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG has achieved an undisclosed milestone payment from Merus N.V. based on Merus’ use of MCLA-158, a bispecific antibody using the GlymaxX antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancing technology in its Phase I trial. The trial in patients with solid tumors will initially focus on metastatic colorectal cancer. MCLA-158 uses ProBioGen’s GlymaxX technology for greater cell-killing potential. GlymaxX is a stable modification, applicable to any producer cell, leading them t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters